- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03578484
Breast Aesthetics by Three Dimensional Measures
Breast Aesthetics by Three Dimensional Measures - A Transatlantic Evaluation of Beauty Ideals Using 3D Scanning and Mammometrics.
Traditionally the measures of the optimally aesthetic breast have been assumed to be static and to represent universal values (1). Measures developed for optimal aesthetic results in breast reduction were derived from brassiere patterns and then applied universally (2). These early and important papers still strongly influence the view of the aesthetics of the breast despite the lack of individualisation and proportion.
To create satisfying results for specific patients, optimal proportions angles and relative measures are needed for each patient. The study will clarify theses measures and provide important guidelines for surgeons.The data will also help define optimal proportional aesthetics in the individual patient.
The concept of universal beauty is unrealistic. It has always been taken for granted that aesthetic values from all cultures are similar. Using 3D scanning on volunteers of youthful age offers a complex set of data that may distinguish fine differences in aesthetic ideals in different cultures.
Little is known about how life events and life-style factors affect breast aesthetics.
To follow a population with 3D scans over 5, 10 and 15 years will allow aesthetic ratings to be correlated with life events such as pregnancy, childbirth, breast-feeding and life style factors such as smoking.
The study will improve the understanding of breast aesthetics in general, in different cultures and in relation to life events and life style factors. No similar studies have previously been performed.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aims for the study:
To identify aesthetic factors that contribute to overall beauty and aesthetics of the breast.
To identify proportions and measures of the most aesthetically pleasing breast and also of the least appealing breast. This will provide a guideline and a map for the reconstructive breast surgeon in what to aim for and what to avoid in the breast reconstructive process.
To identify cultural differences in the perception of beauty.
Aims for the longitudinal part of the study:
To identify lifestyle and life event factors that independently influences the progression of cosmetic ratings and 3D measurements of the breast over 5, 10 and 15 years.
To identify trends and differences in aesthetic ratings of the same 3D scans over time.
Data collection:
At the initial and all following controls of the study a short patient interview will be conducted to obtain the following information:
Subject demographics:
Age, Race, Previous Medical History, Number of Childbirths, Breast feeding - how many children - how many months per child, Surgeries of the breast, Surgeries of the chest wall, Weight, Height, Bra Size, Sports bra use - always - during sports - rarely - never, Smoking, alcohol, Occupation, Physical activity
Measures of the breast will be obtained by 3D scanning.
Rating of the 3D scans will be performed by eight assigned teams:
10 Plastic Surgeons from Scandinavia, 10 Plastic Surgeons from Texas, 10 Scandinavian nurses without formal aesthetic or plastic surgery training, 10 Nurses and/or Physician assistants from the USA without formal aesthetic or plastic surgery training, 10 Medical Students from Texas, 10 Medical Students from Scandinavia, 10 Nursing Students from Texas, 10 Nursing Students from Scandinavia
The 3D scans will be aesthetically rated by independent evaluators on a scale from 1-5. The vertical split plane and the horizontal split plane as defined by Tepper et al (8) in mammometrics will be used to subdivide the breast into aesthetic units.
A separate rating will be obtained for each breast:
Lower pole 1-5, Upper pole 1-5, Medial pole 1-5, Lateral pole 1-5, Nipple position 1-5, Areola color 1-5, Areola size 1-5, Breast footprint position, Overall score
Also both breasts together will be scored regarding:
Intermammary distance / breast cleft, symmetry, overall bilateral score
Data Storage:
The data will be stored for 16 years. The data will be stored in a password -protected computer with firewall protection. The data will be stored in a locked safe.
Statistics:
We will use descriptive statistics such as mean and standard deviation. Various subgroup analyses may occur - continuous variables will be compared using the two sample T-test and parametric variables will be compared using chi-squared analysis or Fischer's exact test. Univariate and multivariate regression models will be used to analyze for confounding factors.
The statistical calculations will be performed in Norway at the Dept of statistics at Rikshospitalet Oslo and/or in collaboration with MD Anderson Cancer Center in Texas, USA.
The rating-system for aesthetics will be tested for reliability. Ten raters will be rating 30 of the same 3D scans twice with a 2 week interval.
Calculation of necessary number of participating women (n) as determined in collaboration with the Dept of Statistics Oslo University:
In the present study a mean score of "overall score bilateral breasts" will be compared in 10 American (Group 1, 3, 5, 7) and 10 Scandinavian/Norwegian (Group 2, 4, 6, 8) plastic surgeons/nurses/medical students/nursing students. We define a mean "overall score bilateral breasts" score difference of at least 0.5 to be a difference of statistical significance. Significance will be defined as p = 0.05. In order to perform a power calculation we need an estimate of the standard deviation (SD) of the scoring of "overall score bilateral breasts" within each group. However such estimates are not available in the literature. We therefore will use the following procedure to calculate (n):
Step 1: Include 10 women and measure average score on "overall score bilateral breasts" for each plastic surgeon. Then calculate SD for each of the average scores in each group. Then we will use these estimates of SD in a power calculation, and calculate the (n) associated with a test power of 80% as per Sandvik.
Our preliminary estimation of power is 150 patients. The somewhat high number is due to potential drop out rates for the longitudinal arm of the study.
Organisation:
Principal Investigator and Conceptual Author: LJ Sandberg Telemark Hospital Trust, Dept of Plastic Surgery, Norway
Collaborators:
Senior author: JC Selber MD Anderson Cancer Center, USA Other authors in random order: G Reece MD Anderson Cancer Center, USA; K Kloster Jensen Telemark Hospital Trust Dept of Plastic Surgery; T Bernklev Telemark Hospital Trust, Dept of Research, Norway; L Sandvik Oslo University, Dept of Statistics, Norway; G Gunnarson Telemark Hospital Trust, Dept of Plastic Surgery, Norway; E Berg Telemark Hospital Trust, Dept of Plastic Surgery, Norway; K Tønseth, Oslo University Hospital, Dept of Plastic Surgery, Norway; HP Gullestad, Oslo University Hospital, Dept of Plastic Surgery, Norway; M Halle Dept of Plastic Surgery, Karolinska Institute Sweden; Å Edsander Nord Dept of Plastic Surgery, Karolinska Institute Sweden; A Höckerstedt Dept of Plastic Surgery, University of Helsinki, Finland; S Kauhanen Dept of Plastic Surgery, University of Helsinki, Finland; E Holm Hansen University Southeast Norway, Norway; Karin Berntsen University Southeast Norway, Norway; Plastic Surgical Department of Statistics at MD Anderson Cancer Center , USA; Department of Statistics at Oslo University, Norway
Canfield Inc / Skintech are not active partners in the project, just partners supplying technology and support. The name of the 3D Vectra system will be used in the paper to scientifically describe the study. Canfield Inc will be mentioned in the Method section of the study as contributing to the study and any conflicts of interests will be disclosed in all and any presentations and publications. No funds have been received from Canfield Inc. Canfield Inc has allowed use of the Vectra 3D camera in the study without any demands or charges.
Clinical Importance:
Aesthetic measures are the basis of all plastic surgical breast procedures and this study will have a major influence on all of plastic surgical procedures of the breast - particularly breast reconstruction. Determining a difference between aesthetic ratings in different cultures would further stress the concept of "beauty lying in the eye of the beholder" and that beauty concepts have to be adapted to the individual and not the other way around. Beauty is not one strict measure, but a range of measures and proportions adapted to the individual subject. The use of 3D scanning is a new technique that offers superior quality documentation and preoperative analysis. The study will further define 3D scanning as a new standard for aesthetic breast evaluations.
In the long term follow up the factors affecting aesthetic ratings over time (aging of the breast), such as smoking, would be revealed. This could further allow life style choices to be made by patients promoting breast aesthetics and hopefully health in general.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway, 0424
- Oslo University Hospital
-
-
Telemark
-
Skien, Telemark, Norway, NO-3710
- Sykehuset Telemark
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- The study will be based on female volunteers between the ages of 18 and 35 of all ethnic backgrounds.
Exclusion Criteria:
- Patients with breast cancer treatment, removal of non-malignant masses, trauma, burns or dermatological diagnoses involving the breast are excluded from the study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Volunteer female subjects
Females age 18-35 years of age.
3D breast scan will be performed and followed over 15 years.
No therapeutic interventions will be performed.
|
Vectra TM - Canfield Inc breast scan.
3D digital photography scan.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Breast aesthetic score in Scandinavia
Time Frame: 5 years
|
Using a rating system developed by Sandberg and Selber for this project, each individual breast (left and right) will be scored according to aesthetic aspects. A score ranging from 1 lowest to 5 highest will be given by the rater. The parameters rated will be breast size, breast width, breast height, breast position, nipple position, nipple shape, nipple color and breast shape. The score will be the outcome measure for the most pleasant aesthetics. |
5 years
|
Breast measures in centimeters and degrees in Scandinavia
Time Frame: 5 years
|
The highest and lowest scored breasts will be measured. Anatomic measures of the breast between fiduciary points, such as distance the nipple and the sternal notch in centimeters. Also measures of angles between the midline and nipple position measured in degrees. Also measures of curvatures in degrees and vectors. The measures will be performed digitally on the 3D scans obtained by the Vectra system for 3D scanning using the software developed by Canfield Inc. This will be the outcome measure in centimeters, degrees and proportions. |
5 years
|
Breast aesthetic score in USA
Time Frame: 5 years
|
Using a rating system developed by Sandberg and Selber for this project, each individual breast (left and right) will be scored according to aesthetic aspects. A score ranging from 1 lowest to 5 highest will be given by the rater. The parameters rated will be breast size, breast width, breast height, breast position, nipple position, nipple shape, nipple color and breast shape. The score will be the outcome measure for the most pleasant aesthetics in the USA. |
5 years
|
Breast measures in centimeters and degrees in USA
Time Frame: 5 years
|
The highest and lowest scored breasts will be measured. Anatomic measures of the breast between fiduciary points, such as distance the nipple and the sternal notch in centimeters. Also measures of angles between the midline and nipple position measured in degrees. Also measures of curvatures in degrees and vectors. The measures will be performed digitally on the 3D scans obtained by the Vectra system for 3D scanning using the software developed by Canfield Inc. This will be the outcome measure in centimeters, degrees and proportions for USA. |
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Breast measures in centimeters and degrees changes at 5 years
Time Frame: 10 years
|
The highest scored breasts will be measured. Anatomic measures of the breast between fiduciary points, such as distance the nipple and the sternal notch in centimeters. Also measures of angles between the midline and nipple position measured in degrees. Also measures of curvatures in degrees and vectors. The measures will be performed digitally on the 3D scans obtained by the Vectra system for 3D scanning using the software developed by Canfield Inc. This will be the outcome measure in centimeters, degrees and proportions to detect change after 5 years. |
10 years
|
Breast measures in centimeters and degrees changes at 10 years
Time Frame: 15 years
|
The highest scored breasts will be measured. Anatomic measures of the breast between fiduciary points, such as distance the nipple and the sternal notch in centimeters. Also measures of angles between the midline and nipple position measured in degrees. Also measures of curvatures in degrees and vectors. The measures will be performed digitally on the 3D scans obtained by the Vectra system for 3D scanning using the software developed by Canfield Inc. This will be the outcome measure in centimeters, degrees and proportions to detect change after 10 years. |
15 years
|
Breast measures in centimeters and degrees changes at 15 years
Time Frame: 16 years
|
The highest scored breasts will be measured. Anatomic measures of the breast between fiduciary points, such as distance the nipple and the sternal notch in centimeters. Also measures of angles between the midline and nipple position measured in degrees. Also measures of curvatures in degrees and vectors. The measures will be performed digitally on the 3D scans obtained by the Vectra system for 3D scanning using the software developed by Canfield Inc. This will be the outcome measure in centimeters, degrees and proportions to detect change after 15 years. |
16 years
|
Change in breast aesthetic score at 5 years
Time Frame: 10 years
|
Using a rating system developed by Sandberg and Selber for this project, each individual breast (left and right) will be scored according to aesthetic aspects. A score ranging from 1 lowest to 5 highest will be given by the rater. The parameters rated will be breast size, breast width, breast height, breast position, nipple position, nipple shape, nipple color and breast shape. The score will be the outcome measure for the change of aesthetics over 5 years. |
10 years
|
Change in breast aesthetic score at 10 years
Time Frame: 15 years
|
Using a rating system developed by Sandberg and Selber for this project, each individual breast (left and right) will be scored according to aesthetic aspects. A score ranging from 1 lowest to 5 highest will be given by the rater. The parameters rated will be breast size, breast width, breast height, breast position, nipple position, nipple shape, nipple color and breast shape. The score will be the outcome measure for the change of aesthetics over 10 years. |
15 years
|
Change in breast aesthetic score at 15 years
Time Frame: 16 years
|
Using a rating system developed by Sandberg and Selber for this project, each individual breast (left and right) will be scored according to aesthetic aspects. A score ranging from 1 lowest to 5 highest will be given by the rater. The parameters rated will be breast size, breast width, breast height, breast position, nipple position, nipple shape, nipple color and breast shape. The score will be the outcome measure for the change of aesthetics over 15 years. |
16 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- PENN J. Breast reduction. Br J Plast Surg. 1955 Jan;7(4):357-71. doi: 10.1016/s0007-1226(54)80046-4. No abstract available.
- WISE RJ. A preliminary report on a method of planning the mammaplasty. Plast Reconstr Surg (1946). 1956 May;17(5):367-75. doi: 10.1097/00006534-195605000-00004. No abstract available.
- Loughry CW, Sheffer DB, Price TE Jr, Lackney MJ, Bartfai RG, Morek WM. Breast volume measurement of 248 women using biostereometric analysis. Plast Reconstr Surg. 1987 Oct;80(4):553-8. doi: 10.1097/00006534-198710000-00013.
- Loughry CW, Sheffer DB, Price TE, Einsporn RL, Bartfai RG, Morek WM, Meli NM. Breast volume measurement of 598 women using biostereometric analysis. Ann Plast Surg. 1989 May;22(5):380-5. doi: 10.1097/00000637-198905000-00002.
- Smith DJ Jr, Palin WE Jr, Katch VL, Bennett JE. Breast volume and anthropomorphic measurements: normal values. Plast Reconstr Surg. 1986 Sep;78(3):331-5. doi: 10.1097/00006534-198609000-00008.
- Losken A, Seify H, Denson DD, Paredes AA Jr, Carlson GW. Validating three-dimensional imaging of the breast. Ann Plast Surg. 2005 May;54(5):471-6; discussion 477-8. doi: 10.1097/01.sap.0000155278.87790.a1.
- Tepper OM, Small K, Rudolph L, Choi M, Karp N. Virtual 3-dimensional modeling as a valuable adjunct to aesthetic and reconstructive breast surgery. Am J Surg. 2006 Oct;192(4):548-51. doi: 10.1016/j.amjsurg.2006.06.026.
- Tepper OM, Unger JG, Small KH, Feldman D, Kumar N, Choi M, Karp NS. Mammometrics: the standardization of aesthetic and reconstructive breast surgery. Plast Reconstr Surg. 2010 Jan;125(1):393-400. doi: 10.1097/PRS.0b013e3181c4966e. No abstract available.
- Rohrich RJ, Bolden K. Ethnic rhinoplasty. Clin Plast Surg. 2010 Apr;37(2):353-70. doi: 10.1016/j.cps.2009.11.006.
- Li Z, Unger JG, Roostaeian J, Constantine F, Rohrich RJ. Individualized Asian rhinoplasty: a systematic approach to facial balance. Plast Reconstr Surg. 2014 Jul;134(1):24e-32e. doi: 10.1097/PRS.0000000000000294.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 44059 / 3 / MSS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Aesthetic assessment 3D breast scanning
-
University of PecsCompletedScoliosis Idiopathic | Scoliosis, SevereHungary
-
British Columbia Children's HospitalUniversity of British ColumbiaUnknownDevelopmental Dysplasia of the HipCanada
-
Mentor Worldwide, LLCActive, not recruitingPrimary Breast Augmentation | Primary Breast Reconstruction | Revision Breast Augmentation | Revision Breast ReconstructionUnited States
-
Stanford UniversityRecruiting
-
Helix Medical SystemsTerminated
-
University of Texas Southwestern Medical CenterCompleted
-
University of California, DavisHologic, Inc.CompletedBreast CancerUnited States
-
Tang-Du HospitalUnknownBreast Neoplasms | DWIChina
-
University of PecsCompleted
-
University of MichiganRecruitingMaxillofacial Abnormalities | Craniofacial Abnormalities | Prosthetic TreatmentUnited States